|
|
|
|
|
|
Vertex Pharmaceuticals specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows:
- income from sales of products (87.3%);
- royalties (9.3%);
- income from partnership, research, and development agreements (3.4%): partnership agreements with Mitsubishi Tanabe (36.2% of net sales), CFFT (32.6%), Janssen (31.1%) and other (0.1%).
|
|
| Surperformance© rating of Vertex Pharmaceuticals Inc | |
|
|
Overall rating |
In sector |
In country |
| Trading Rating |
|
|
|
| Investor Rating |
|
|
|
| Growth (Revenue) |
|
|
|
| Valuation |
|
|
|
| Finances |
|
|
|
| Profitability |
|
|
|
| Earnings quality |
|
|
|
| Business Predictability |
|
|
|
| PER |
- |
- |
- |
| Potential |
|
|
|
| Yield |
- |
- |
- |
| Consensus |
|
|
|
| 7 days EPS revision |
|
|
|
| 4 months EPS revision |
|
|
|
| 1 year EPS revision |
|
|
|
| 4 months Revenue revision |
|
|
|
| 1 year Revenue revision |
|
|
|
| |
|
|
|
|
Data source :
© 2013 Thomson Reuters |
|
Ratings :
© 2013 Surperformance |
|
|
|
|
|
| - FMR LLC |
11,30% |
| - Blackrock |
7,30% |
| - T. Rowe Price Associates |
7,00% |
| - The Growth Fund of America |
6,10% |
| - Capital World Investors |
5,70% |
| - Managers and Directors |
3,10% |
| - Mister Joshua S. Boger |
1,50% |
|
|
|
|
- Investor Relations :
Michael Partridge |
- Chief Financial Officer :
Ian F. Smith |
- Chief Executive Officer :
Jeffrey Leiden |
- General Secretary :
Kenneth S. Boger |
|
|
| Company contact information |
|
130 Waverly Street
MA 02139 Cambridge
USA
Phone : +1 617 444 6100
Fax : +1 617 444 6680
Internet : http://www.vpharm.com
|
|
|
|
- NASDAQ All Markets - Nasdaq Global Select Market - Nasdaq 100 / |
|
|
|
|
| - ISIN Code : |
US92532F1003 |
| - Bloomberg Code : |
VRTX:US |
| - Reuters Code : |
VRTX.O |
| - Datastream Code : |
|
|
Financial data source :
© 2013 Cofisem |
|
|
